Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, comments on the chronic lymphocytic leukemia (CLL) treatment landscape and suggests how these therapies may evolve in the future. Prof. Kater argues that despite significant growth in terms of drugs and treatment combinations for CLL, chemotherapy is still relevant for patients with a mutation in IgVH. In addition, Prof. Kater underlines the necessity of focusing on personalizing these novel therapies for each patient. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.